We investigated the tumour immune microenvironment—in particular the presence of PD-L1, T-cells, IDO, TDO, MMRp and cancer-associated fibroblasts (CAFs)—in tissue from patients with treatment-naive serotonin-producing (SP) and non-serotonin-producing NET (NSP-NET) grade 1 or 2 in this exploratory study. This evidence concerns the gene TDO2 and neoplasm.